Bhatia Smita, Yasui Yutaka, Robison Leslie L, Birch Jillian M, Bogue Monica K, Diller Lisa, DeLaat Cyndi, Fossati-Bellani Franca, Morgan Elaine, Oberlin Odile, Reaman Gregory, Ruymann Frederick B, Tersak Jean, Meadows Anna T
City of Hope National Medical Center, 1500 E Duarte Rd, Duarte, CA 91010-3000, USA.
J Clin Oncol. 2003 Dec 1;21(23):4386-94. doi: 10.1200/JCO.2003.11.059.
We present an update of a previously reported Late Effects Study Group cohort of 1,380 children with Hodgkin's disease (HD) diagnosed between 1955 and 1986 in patients aged 16 years or younger. We describe the pattern and incidence of subsequent neoplasms (SNs) occurring with extended follow-up.
Median age at diagnosis of HD was 11.7 years (range, 0.3 to 16.9 years) and at last follow-up was 27.8 years. Median length of follow-up was 17.0 years.
An additional 103 SNs were ascertained (total SNs = 212). The cohort was at an 18.5-fold increased risk of developing SNs compared with the general population (standardized incidence ratio [SIR], 18.5, 95% CI, 15.6 to 21.7). The cumulative incidence of any second malignancy was 10.6% at 20 years, increasing to 26.3% at 30 years; and of solid malignancies was 7.3% at 20 years, increasing to 23.5% at 30 years. Breast cancer was the most common solid malignancy (SIR, 56.7). Other commonly occurring solid malignancies included thyroid cancer (SIR, 36.4), bone tumors (SIR, 37.1), and colorectal (SIR, 36.4), lung (SIR, 27.3), and gastric cancers (SIR, 63.9). Risk factors for solid tumors included young age at HD and radiation-based therapy. Thirty-two patients developed third neoplasms, with the cumulative incidence approaching 21% at 10 years from diagnosis of second malignancy.
Additional follow-up of this large cohort of HD survivors documents an increasing occurrence of known radiation-associated solid tumors, (breast and thyroid cancers), as well as emergence of epithelial neoplasms common in adults, (colon and lung cancers) at a younger age than expected in the general population, necessitating ongoing surveillance of this high risk population.
我们对先前报道的晚期效应研究组队列进行了更新,该队列包括1955年至1986年间确诊的1380例16岁及以下的霍奇金淋巴瘤(HD)患儿。我们描述了延长随访期内发生的后续肿瘤(SNs)的模式和发病率。
HD诊断时的中位年龄为11.7岁(范围0.3至16.9岁),最后一次随访时为27.8岁。中位随访时间为17.0年。
又确诊了103例SNs(SNs总数 = 212)。与一般人群相比,该队列发生SNs的风险增加了18.5倍(标准化发病率[SIR],18.5,95%可信区间,15.6至21.7)。任何第二种恶性肿瘤的累积发病率在20年时为10.6%,在30年时增至26.3%;实体恶性肿瘤在20年时为7.3%,在30年时增至23.5%。乳腺癌是最常见的实体恶性肿瘤(SIR,56.7)。其他常见的实体恶性肿瘤包括甲状腺癌(SIR,36.4)、骨肿瘤(SIR,37.1)、结直肠癌(SIR,36.4)、肺癌(SIR,27.3)和胃癌(SIR,63.9)。实体肿瘤的危险因素包括HD诊断时年龄小和接受放疗。32例患者发生了第三种肿瘤,从第二种恶性肿瘤诊断起10年时累积发病率接近21%。
对这一大型HD幸存者队列的进一步随访表明,已知的与放疗相关的实体肿瘤(乳腺癌和甲状腺癌)的发生率不断增加,以及成人中常见的上皮性肿瘤(结肠癌和肺癌)在比一般人群预期更年轻的年龄出现,因此有必要对这一高危人群进行持续监测。